GlobeNewsWire
29 May 2026, 18:48 UTC · 1h ago
Source · https://www.globenewswire.com/news-release/2026/05/29/3303781/32716/en/Gossamer-Bio-Inc-GOSS-Faces-Securities-Class-Action-Amid-80-Drop-On-Phase-3-PROSERA-Trial-Failure-HBSS.html
Read source
Search tags
Story key points
4 claims · impact-rated
Gossamer Bio's Phase 3 PROSERA study for seralutinib failed to meet its primary endpoint for treating pulmonary arterial hypertension. — The failure of a flagship Phase 3 trial removes the primary catalyst for company growth and value.
-1.00Gossamer Bio's share price dropped 80% following the trial failure announcement. — This reflects a massive loss in market capitalization and investor confidence in the company's pipeline.
-0.80Gossamer Bio has failed to meet the $1 minimum share bid price required for continued listing on the Nasdaq Global Select Market. — Risk of delisting significantly increases volatility and reduces liquidity for remaining shareholders.
-0.70Continue reading
6 related stories
A securities class action lawsuit has been filed alleging Gossamer misled investors regarding trial design and patient recruitment. — Legal liabilities and potential settlements create additional financial overhang and reputational risk.
Ticker attribution
Model heads
The company faces a securities class action lawsuit following a Phase 3 trial failure and an 80% drop in stock price.
The article mentions the 'highly successful' Merck Phase 3 STELLAR study as a benchmark for the disease area.
Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
